Cargando…

Lanadelumab for hereditary angioedema

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2022
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081937/ https://www.ncbi.nlm.nih.gov/pubmed/35592365 http://dx.doi.org/10.18773/austprescr.2022.017

Ejemplares similares

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Acebrophylline-induced angioedema
por: Kuriachan, Sanitha, et al.
Publicado: (2015)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Acute dystonic reaction leading to lingual hematoma mimicking angioedema
por: Sezer, Özgür, et al.
Publicado: (2017)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Fostemsavir for HIV-1 infection
Publicado: (2022)

Eptinezumab for migraine
Publicado: (2022)

Larotrectinib for solid tumours
Publicado: (2022)

Alpelisib for breast cancer
Publicado: (2022)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Sacituzumab govitecan for breast cancer
Publicado: (2022)

Elotuzumab for multiple myeloma
Publicado: (2022)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Cabotegravir
Publicado: (2022)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Pemigatinib for cholangiocarcinoma
Publicado: (2022)

Selinexor for multiple myeloma
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j2vfr1q7v425cipb30j3iqi5it